Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis

Na, Heya; Liu, Xiaoli; Li, Xiaomeng; Zhang, Xinsheng; Wang, Yu; Wang, Zhaohui; Yuan, Ming; Ren, Shuo; Zuo, Yongchun

doi:10.1186/s13045-016-0383-x

Cited by 42 publications

(42 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, a gradual increase in the genesis of hepatic sinusoids and the surrounding vasculature may provide sufficient nutrition and oxygen proportional to the growth of the tumor, whilst allowing it time to adapt to the immune pressures of the host environment. Furthermore, it has been demonstrated that CLEC4M enhances the mobility and invasiveness of tumor cells in gastric and colon cancer (13,21). Additionally, high CLEC4M expression in HCC tissues is associated with a poorer prognosis, which is consistent with previous literature on lung (38) and cervical cancer (39).…”

Section: Clec4m Expression ------------------------------------------supporting

confidence: 88%

“…Several studies have demonstrated the involvement of CLEC4M in colon and gastric cancer progression. For example, CLEC4M is associated with poor prognosis in patients with colon cancer, and it is involved in the adhesion, migration, invasion and liver metastasis of colon cancer cells (21). Furthermore, CLEC4M exerts these biological functions through the signal transducer and activator of transcription 5/long non-coding RNA Heterogeneous Nuclear Ribonucleoprotein K Pseudogene 2/ C-X-C chemokine receptor type 4 axis (13).…”

Section: High Expression Levels Of Clec4m Indicate Poor Prognosis In mentioning

confidence: 99%

See 1 more Smart Citation

High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma

Luo

Zhao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The identification of novel and accurate biomarkers is important to improve the prognosis of patients with hepatocellular carcinoma (HCC). C-Type lectin domain family 4 member M (CLEC4M) is involved in the progression of numerous cancer types. However, the clinical significance of CLEC4M in HCC is yet to be elucidated. The aim of the present study is to evaluate the involvement of CLEC4M in HCC progression. The expression level of CLEC4M was determined in tumor, and their corresponding adjacent non-tumor tissues derived from 88 patients with HCC, using immunohistochemistry, western blot and reverse transcription-quantitative PCR. The correlation between CLEC4M expression and certain clinicopathological characteristics was retrospectively analyzed. The results suggested that CLEC4M was specifically labeled in sinusoidal endothelial cells, in both HCC and non-tumor tissues. Moreover, the expression of CLEC4M in tumor tissues was significantly lower than that in non-tumor tissues (P<0.0001), which indicated its potential as a biomarker of the development of HCC. Subsequently, correlation analysis suggested that the relatively higher CLEC4M expression in HCC tissues was significantly associated with increased microvascular invasion (P= 0.008), larger tumor size (P= 0.018), absence of tumor encapsulation (P<0.0001) and lower tumor differentiation (P= 0.019). Notably, patients with high CLEC4M expression levels in their tumor tissues experienced more frequent recurrence and shorter overall survival (OS) times compared with the low-expression group. Furthermore, CLEC4M expression in tumor tissues was identified as an independent and significant risk factor for recurrence-free survival and OS. The results of the present study suggest that CLEC4M may be a valuable biomarker for the prognosis of the patients with HCC, postoperatively.

show abstract

Section: Clec4m Expression ------------------------------------------supporting

confidence: 88%

Section: High Expression Levels Of Clec4m Indicate Poor Prognosis In mentioning

confidence: 99%

High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma

Luo

Zhao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…For the reactome pathway enrichment analysis, the upregulated genes mostly focused on regulation of the immune system and inflammation and cancer cell invasion and metastasis [36,37]. The downregulated genes played important roles in CRC-related pathways involving in preneoplastic lesions, carcinogenesis, metastasis, and poor prognosis [38][39][40].…”

Section: Discussionmentioning

confidence: 99%

Identification of Hub Genes Related to Carcinogenesis and Prognosis in Colorectal Cancer Based on Integrated Bioinformatics

Gong

Kao

Zhang

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

The high mortality of colorectal cancer (CRC) patients and the limitations of conventional tumor-node-metastasis (TNM) stage emphasized the necessity of exploring hub genes closely related to carcinogenesis and prognosis in CRC. The study is aimed at identifying hub genes associated with carcinogenesis and prognosis for CRC. We identified and validated 212 differentially expressed genes (DEGs) from six Gene Expression Omnibus (GEO) datasets and the Cancer Genome Atlas (TCGA) database. We investigated functional enrichment analysis for DEGs. The protein-protein interaction (PPI) network was constructed, and hub modules and genes in CRC carcinogenesis were extracted. A prognostic signature was developed and validated based on Cox proportional hazards regression analysis. The DEGs mainly regulated biological processes covering response to stimulus, metabolic process, and affected molecular functions containing protein binding and catalytic activity. The DEGs played important roles in CRC-related pathways involving in preneoplastic lesions, carcinogenesis, metastasis, and poor prognosis. Hub genes closely related to CRC carcinogenesis were extracted including six genes in model 1 (CXCL1, CXCL3, CXCL8, CXCL11, NMU, and PPBP) and two genes and Metallothioneins (MTs) in model 2 (SLC26A3 and SLC30A10). Among them, CXCL8 was also related to prognosis. An eight-gene signature was proposed comprising AMH, WBSCR28, SFTA2, MYH2, POU4F1, SIX4, PGPEP1L, and PAX5. The study identified hub genes in CRC carcinogenesis and proposed an eight-gene signature with good reproducibility and robustness at the molecular level for CRC, which might provide directive significance for treatment selection and survival prediction.

show abstract

“…Colorectal cancer (CRC) is one of the most common malignancies of gastrointestinal system (1). Although the treatment of CRC has been developed substantially in the past decades, the prognosis of CRC remains unsatisfactory (2,3). Therefore, there is still an urgent clinical need to explore new and effective drugs for the treatment of CRC.…”

Section: Introductionmentioning

confidence: 99%

BMP7 mediates the anticancer effect of honokiol by upregulating p53 in HCT116 cells

Liu

Ren

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second leading cause of cancer death. Hence, there is a great need to explore new efficacious drugs for the treatment of CRC. Honokiol (HNK), a natural product extracted from magnolia bark, processes various biological activities, including anticancer. In this study, we introduced cell viability assay, western blotting, real-time PCR and immunofluorescent staining to determine the anticancer effect of HNK, and the possible mechanism underlying this biological process. We found that HNK can inhibit the proliferation and induce apoptosis in HCT116 cells in a concentration- and time-dependent manner. HNK activates p53 in HCT116 and other colon cancer cells. Exogenous p53 potentiates the anticancer of HNK, while p53 inhibitor decreases this effect of HNK. Moreover, HNK upregulates the expression of bone morphogenetic protein 7 (BMP7) in colon cancer cells; Exogenous BMP7 enhances the anticancer activity of HNK and BMP7 specific antibody reduces this effect of HNK. For mechanism, we found that HNK cannot increase the level of Smad1/5/8; Exogenous BMP7 potentiates the HNK-induced activation of p53. On the contrary, BMP7 specific antibody inhibits the HNK-induced activation of p53 in colon cancer cells and partly decreases the total level of p53. Our findings suggested that HNK may be a promising anticancer drug for CRC; activation of p53 plays an important role in the anticancer activity of HNK, which may be initialized partly by the HNK-induced upregulation of BMP7.

show abstract

Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis

Cited by 42 publications

References 57 publications

High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma

High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma

Identification of Hub Genes Related to Carcinogenesis and Prognosis in Colorectal Cancer Based on Integrated Bioinformatics

BMP7 mediates the anticancer effect of honokiol by upregulating p53 in HCT116 cells

Contact Info

Product

Resources

About